Abstract | OBJECTIVES: METHODS: Analysis comprised HIV-positive patients in the ICoNA study without acute hepatitis who had >or= 1 positive HCV antibody test and > 1 positive HBV surface antigen test. LEE was defined as > 5x baseline alanine aminotransferase (ALT) or > 3.5x baseline if the baseline was > 40 IU/l. Analysis used Poisson regression with generalized estimating equation correction to examine HBV or HCV co-infection, use of HAART, baseline ALT and demographics as LEE predictors. RESULTS: Of the 5272 patients, 47.6% were co-infected with HCV/HBV; 29.9% were female and 39% were intravenous drug users. There were 275 episodes of LEE during 18 259 person-years follow up. Taking HAART did not significantly increase risk of LEE [adjusted relative risk (RR), 1.19; 95% confidence interval (CI), 0.81-1.75; P = 0.37]. Co-infection increased the risk of LEE (adjusted RR, 5.07; 95% CI, 3.47-7.48; P < 0.001), with no significant differences if taking HAART (adjusted RR, 4.99; 95% CI, 3.38-7.37) or not (adjusted RR, 6.02; 95% CI, 2.02-17.98) (P = 0.74 for interaction). Females were at lower risk of LEE than males (adjusted RR, 0.59; 95% CI, 0.42-0.83; P = 0.02). CONCLUSIONS: HIV and HBV/HCV co-infection per se is associated with increased risk of LEE that is not modified by HAART. The recommendation for caution in HAART use in co-infected patients, simply based on a high rate of LEE in people on therapy, may be questionable.
|
Authors | Paola Cicconi, Alessandro Cozzi-Lepri, Andrew Phillips, Massimo Puoti, Giorgio Antonucci, Paolo E Manconi, Giulia Tositti, Vincenzo Colangeli, Miriam Lichtner, Antonella d'arminio Monforte, ICoNA Study Group |
Journal | AIDS (London, England)
(AIDS)
Vol. 21
Issue 5
Pg. 599-606
(Mar 12 2007)
ISSN: 0269-9370 [Print] England |
PMID | 17314522
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-HIV Agents
- Alanine Transaminase
|
Topics |
- Adult
- Alanine Transaminase
(blood)
- Anti-HIV Agents
(adverse effects)
- Antiretroviral Therapy, Highly Active
(adverse effects)
- Female
- Follow-Up Studies
- HIV Infections
(complications, drug therapy, enzymology)
- Hepatitis B, Chronic
(complications, enzymology)
- Hepatitis C, Chronic
(complications, enzymology)
- Humans
- Liver
(drug effects, enzymology)
- Male
- Risk Assessment
|